 Amrut Ambardekar
Concepts (417)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 36 | 2023 | 485 | 8.680 |
Why?
| | Heart Failure | 50 | 2023 | 1962 | 6.760 |
Why?
| | Heart Transplantation | 23 | 2023 | 669 | 5.190 |
Why?
| | Amyloidosis | 4 | 2023 | 36 | 1.900 |
Why?
| | Heart Ventricles | 9 | 2020 | 714 | 1.690 |
Why?
| | Cardiomyopathies | 7 | 2023 | 300 | 1.490 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2020 | 351 | 1.190 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2023 | 361 | 1.100 |
Why?
| | Myocardium | 10 | 2023 | 922 | 1.000 |
Why?
| | Arrhythmias, Cardiac | 6 | 2022 | 278 | 0.920 |
Why?
| | Myocytes, Cardiac | 11 | 2023 | 448 | 0.890 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 218 | 0.880 |
Why?
| | Humans | 97 | 2023 | 115039 | 0.880 |
Why?
| | Defibrillators, Implantable | 4 | 2020 | 286 | 0.850 |
Why?
| | Rejuvenation | 1 | 2022 | 14 | 0.820 |
Why?
| | Assisted Circulation | 2 | 2021 | 25 | 0.800 |
Why?
| | Fibrosis | 5 | 2022 | 454 | 0.800 |
Why?
| | Transplant Recipients | 4 | 2021 | 143 | 0.790 |
Why?
| | Echocardiography | 7 | 2017 | 557 | 0.790 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 46 | 0.790 |
Why?
| | Hemodynamics | 7 | 2023 | 1017 | 0.780 |
Why?
| | Vascular Stiffness | 2 | 2017 | 408 | 0.770 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 651 | 0.740 |
Why?
| | Stroke Volume | 8 | 2023 | 510 | 0.730 |
Why?
| | Calcineurin Inhibitors | 1 | 2021 | 58 | 0.730 |
Why?
| | Giant Cells | 1 | 2020 | 21 | 0.730 |
Why?
| | Arteries | 1 | 2022 | 249 | 0.710 |
Why?
| | Ventricular Function, Left | 7 | 2023 | 469 | 0.710 |
Why?
| | Aortic Diseases | 1 | 2021 | 108 | 0.700 |
Why?
| | Heart Neoplasms | 1 | 2020 | 49 | 0.700 |
Why?
| | Sarcoma, Kaposi | 1 | 2020 | 69 | 0.690 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 252 | 0.670 |
Why?
| | Middle Aged | 33 | 2022 | 26827 | 0.660 |
Why?
| | Myocarditis | 1 | 2020 | 93 | 0.660 |
Why?
| | Coronary Vessels | 2 | 2018 | 230 | 0.660 |
Why?
| | Graft Rejection | 3 | 2021 | 522 | 0.640 |
Why?
| | Brugada Syndrome | 2 | 2009 | 9 | 0.630 |
Why?
| | Myocardial Contraction | 4 | 2020 | 313 | 0.620 |
Why?
| | Bariatric Surgery | 1 | 2021 | 162 | 0.620 |
Why?
| | Heart | 6 | 2023 | 610 | 0.610 |
Why?
| | Extracellular Matrix | 1 | 2021 | 436 | 0.600 |
Why?
| | Male | 45 | 2022 | 55730 | 0.600 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 227 | 0.570 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 236 | 0.550 |
Why?
| | Female | 45 | 2022 | 59611 | 0.550 |
Why?
| | Thrombosis | 2 | 2016 | 301 | 0.510 |
Why?
| | Heart Rate | 2 | 2021 | 705 | 0.510 |
Why?
| | Cryosurgery | 1 | 2016 | 52 | 0.510 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 207 | 0.480 |
Why?
| | Blood Pressure | 5 | 2022 | 1539 | 0.480 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 153 | 0.460 |
Why?
| | Aged | 19 | 2022 | 19119 | 0.450 |
Why?
| | Electrocardiography | 4 | 2020 | 562 | 0.450 |
Why?
| | Marijuana Abuse | 1 | 2016 | 212 | 0.450 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 463 | 0.430 |
Why?
| | Treatment Outcome | 12 | 2021 | 9122 | 0.430 |
Why?
| | Aorta, Thoracic | 1 | 2015 | 257 | 0.420 |
Why?
| | Myofibrils | 3 | 2022 | 46 | 0.410 |
Why?
| | Adult | 21 | 2023 | 30655 | 0.410 |
Why?
| | Patient-Centered Care | 2 | 2021 | 474 | 0.410 |
Why?
| | Guideline Adherence | 3 | 2011 | 492 | 0.390 |
Why?
| | Patient Compliance | 2 | 2017 | 524 | 0.370 |
Why?
| | Cardiology | 2 | 2023 | 259 | 0.360 |
Why?
| | Recovery of Function | 2 | 2011 | 575 | 0.360 |
Why?
| | Risk Assessment | 6 | 2021 | 2976 | 0.350 |
Why?
| | Calcium | 4 | 2023 | 1104 | 0.350 |
Why?
| | Cardiac Tamponade | 1 | 2010 | 14 | 0.350 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2098 | 0.350 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 155 | 0.340 |
Why?
| | Cannabis | 1 | 2016 | 383 | 0.340 |
Why?
| | Hospitals, Rural | 1 | 2009 | 31 | 0.340 |
Why?
| | Electric Stimulation Therapy | 1 | 2010 | 56 | 0.340 |
Why?
| | Sarcomeres | 3 | 2022 | 90 | 0.330 |
Why?
| | Baroreflex | 2 | 2021 | 54 | 0.330 |
Why?
| | Cardiac Output | 3 | 2023 | 143 | 0.330 |
Why?
| | Automobile Driving | 1 | 2011 | 128 | 0.330 |
Why?
| | Safety | 1 | 2011 | 297 | 0.330 |
Why?
| | Hospitals, Urban | 1 | 2009 | 127 | 0.330 |
Why?
| | Registries | 6 | 2021 | 1763 | 0.330 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 79 | 0.320 |
Why?
| | Pulsatile Flow | 2 | 2018 | 54 | 0.310 |
Why?
| | Counseling | 1 | 2011 | 342 | 0.310 |
Why?
| | Vascular Remodeling | 2 | 2021 | 153 | 0.310 |
Why?
| | Length of Stay | 2 | 2009 | 950 | 0.310 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2023 | 38 | 0.300 |
Why?
| | Mastitis | 1 | 2007 | 4 | 0.300 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1355 | 0.300 |
Why?
| | Prospective Studies | 10 | 2021 | 6232 | 0.290 |
Why?
| | Puerperal Disorders | 1 | 2007 | 30 | 0.290 |
Why?
| | Retrospective Studies | 13 | 2023 | 12547 | 0.290 |
Why?
| | Coronary Disease | 1 | 2009 | 347 | 0.290 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 314 | 0.280 |
Why?
| | Environment | 1 | 2009 | 335 | 0.280 |
Why?
| | Follow-Up Studies | 6 | 2021 | 4420 | 0.270 |
Why?
| | HIV Infections | 1 | 2020 | 2470 | 0.270 |
Why?
| | Diastole | 2 | 2018 | 131 | 0.260 |
Why?
| | Inpatients | 1 | 2009 | 378 | 0.260 |
Why?
| | Troponin I | 2 | 2019 | 68 | 0.250 |
Why?
| | Quality of Health Care | 1 | 2009 | 573 | 0.240 |
Why?
| | Perioperative Care | 2 | 2017 | 125 | 0.230 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 10 | 0.220 |
Why?
| | MicroRNAs | 2 | 2022 | 603 | 0.220 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 1901 | 0.220 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 36 | 0.210 |
Why?
| | Preoperative Care | 2 | 2017 | 318 | 0.210 |
Why?
| | Patient Transfer | 2 | 2019 | 144 | 0.210 |
Why?
| | Quality of Life | 5 | 2023 | 2359 | 0.210 |
Why?
| | Cohort Studies | 6 | 2023 | 4904 | 0.210 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 29 | 0.210 |
Why?
| | Heart Injuries | 1 | 2023 | 36 | 0.210 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 76 | 0.210 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 387 | 0.210 |
Why?
| | Metalloproteases | 1 | 2022 | 37 | 0.200 |
Why?
| | Cadherin Related Proteins | 1 | 2022 | 12 | 0.200 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 10 | 0.200 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 10 | 0.200 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 15 | 0.200 |
Why?
| | Succinic Acid | 2 | 2019 | 44 | 0.200 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 123 | 0.190 |
Why?
| | Leukopenia | 1 | 2021 | 27 | 0.190 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 16 | 0.190 |
Why?
| | Hypertension | 2 | 2020 | 1058 | 0.190 |
Why?
| | Cardiovascular System | 1 | 2023 | 126 | 0.190 |
Why?
| | Case-Control Studies | 4 | 2022 | 3015 | 0.190 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 205 | 0.190 |
Why?
| | Carrier Proteins | 2 | 2022 | 696 | 0.190 |
Why?
| | Heart Failure, Systolic | 1 | 2021 | 20 | 0.190 |
Why?
| | Hospitalization | 3 | 2022 | 1754 | 0.190 |
Why?
| | Pressoreceptors | 1 | 2021 | 18 | 0.180 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 78 | 0.180 |
Why?
| | Alternative Splicing | 1 | 2022 | 188 | 0.180 |
Why?
| | Myocardial Infarction | 2 | 2023 | 930 | 0.180 |
Why?
| | Muscle Proteins | 1 | 2022 | 210 | 0.180 |
Why?
| | Cell Adhesion | 2 | 2018 | 430 | 0.180 |
Why?
| | Disease Progression | 2 | 2018 | 2389 | 0.170 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1634 | 0.170 |
Why?
| | Cardiomyopathy, Hypertrophic | 1 | 2021 | 122 | 0.170 |
Why?
| | United States | 9 | 2023 | 12224 | 0.170 |
Why?
| | Consensus | 4 | 2023 | 534 | 0.170 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 91 | 0.170 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2551 | 0.170 |
Why?
| | Terminology as Topic | 1 | 2020 | 186 | 0.170 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 249 | 0.160 |
Why?
| | HIV | 1 | 2020 | 208 | 0.160 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2389 | 0.160 |
Why?
| | Mice | 11 | 2023 | 14927 | 0.160 |
Why?
| | Prognosis | 4 | 2021 | 3334 | 0.160 |
Why?
| | Exercise Test | 4 | 2023 | 545 | 0.160 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 267 | 0.160 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 182 | 0.160 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 344 | 0.160 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 174 | 0.150 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 225 | 0.150 |
Why?
| | Filamins | 1 | 2018 | 19 | 0.150 |
Why?
| | Aortic Valve | 1 | 2022 | 399 | 0.150 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 172 | 0.150 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 220 | 0.150 |
Why?
| | Mutation | 2 | 2018 | 3350 | 0.150 |
Why?
| | Pilot Projects | 3 | 2019 | 1375 | 0.150 |
Why?
| | Recurrence | 1 | 2020 | 941 | 0.150 |
Why?
| | Transcriptome | 2 | 2020 | 725 | 0.150 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 10 | 0.140 |
Why?
| | Brain | 2 | 2018 | 2379 | 0.140 |
Why?
| | Animals | 14 | 2023 | 31867 | 0.140 |
Why?
| | Anesthetics | 1 | 2017 | 55 | 0.140 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 140 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2018 | 249 | 0.140 |
Why?
| | ErbB Receptors | 1 | 2020 | 555 | 0.140 |
Why?
| | Caliciviridae Infections | 1 | 2016 | 17 | 0.140 |
Why?
| | Transition to Adult Care | 1 | 2017 | 63 | 0.140 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 225 | 0.140 |
Why?
| | Cell Differentiation | 2 | 2021 | 1700 | 0.140 |
Why?
| | Down-Regulation | 2 | 2016 | 599 | 0.140 |
Why?
| | Self Care | 1 | 2019 | 351 | 0.140 |
Why?
| | Prosthesis Design | 3 | 2014 | 285 | 0.130 |
Why?
| | Polypharmacy | 1 | 2017 | 74 | 0.130 |
Why?
| | Histone Deacetylases | 1 | 2018 | 196 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 937 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 447 | 0.130 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2018 | 236 | 0.130 |
Why?
| | Eligibility Determination | 1 | 2016 | 60 | 0.130 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 62 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1523 | 0.130 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1006 | 0.130 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 370 | 0.130 |
Why?
| | Drug Interactions | 1 | 2017 | 347 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2021 | 647 | 0.130 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 68 | 0.130 |
Why?
| | Biomarkers | 3 | 2023 | 3419 | 0.130 |
Why?
| | Postoperative Care | 1 | 2017 | 222 | 0.130 |
Why?
| | Tacrolimus | 1 | 2016 | 135 | 0.130 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 275 | 0.130 |
Why?
| | Hospital Mortality | 2 | 2009 | 776 | 0.130 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2015 | 53 | 0.130 |
Why?
| | Phosphorylation | 3 | 2019 | 1572 | 0.130 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1080 | 0.120 |
Why?
| | Viscosity | 1 | 2015 | 82 | 0.120 |
Why?
| | Health Status | 1 | 2019 | 722 | 0.120 |
Why?
| | Prescription Drugs | 1 | 2016 | 116 | 0.120 |
Why?
| | Cardiovascular Agents | 2 | 2020 | 125 | 0.120 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 51 | 0.120 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 608 | 0.120 |
Why?
| | Rats | 5 | 2022 | 4973 | 0.120 |
Why?
| | Elastic Modulus | 1 | 2015 | 116 | 0.120 |
Why?
| | Atherosclerosis | 1 | 2018 | 342 | 0.120 |
Why?
| | Vaccination | 1 | 2022 | 1205 | 0.110 |
Why?
| | Incidence | 3 | 2019 | 2318 | 0.110 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1317 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2017 | 478 | 0.110 |
Why?
| | Attitude to Health | 1 | 2017 | 405 | 0.110 |
Why?
| | Hip Prosthesis | 1 | 2014 | 33 | 0.110 |
Why?
| | Systole | 1 | 2014 | 171 | 0.110 |
Why?
| | Quality Improvement | 1 | 2021 | 953 | 0.110 |
Why?
| | Patient Selection | 2 | 2017 | 646 | 0.110 |
Why?
| | Shock, Cardiogenic | 1 | 2014 | 53 | 0.110 |
Why?
| | Time Factors | 4 | 2023 | 6141 | 0.110 |
Why?
| | Young Adult | 6 | 2019 | 10498 | 0.110 |
Why?
| | Liver Transplantation | 1 | 2020 | 774 | 0.110 |
Why?
| | Prosthesis Failure | 1 | 2014 | 116 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2017 | 682 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2016 | 223 | 0.110 |
Why?
| | Blood Coagulation | 1 | 2014 | 221 | 0.110 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 976 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2016 | 593 | 0.100 |
Why?
| | Ventricular Premature Complexes | 1 | 2012 | 26 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2799 | 0.100 |
Why?
| | Risk Factors | 4 | 2020 | 8642 | 0.100 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 8 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1046 | 0.090 |
Why?
| | Decision Making | 1 | 2017 | 782 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 2 | 2010 | 814 | 0.090 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 77 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2329 | 0.090 |
Why?
| | Stroke | 1 | 2019 | 1015 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2022 | 154 | 0.090 |
Why?
| | Connectin | 2 | 2022 | 30 | 0.090 |
Why?
| | Endpoint Determination | 2 | 2020 | 69 | 0.090 |
Why?
| | Exercise | 1 | 2020 | 1644 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1715 | 0.090 |
Why?
| | Anticoagulants | 1 | 2014 | 546 | 0.090 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 159 | 0.090 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2011 | 133 | 0.090 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 180 | 0.090 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 126 | 0.090 |
Why?
| | Comorbidity | 2 | 2020 | 1457 | 0.090 |
Why?
| | Pericardial Effusion | 1 | 2010 | 21 | 0.090 |
Why?
| | Heart Septum | 1 | 2009 | 26 | 0.080 |
Why?
| | DNA | 1 | 2016 | 1352 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2022 | 3545 | 0.080 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 67 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2022 | 3896 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1184 | 0.080 |
Why?
| | Ultrasonography | 1 | 2012 | 636 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 294 | 0.080 |
Why?
| | Europe | 2 | 2020 | 336 | 0.080 |
Why?
| | Transcription Factors | 1 | 2016 | 1531 | 0.080 |
Why?
| | Coronary Circulation | 1 | 2008 | 135 | 0.080 |
Why?
| | Syndrome | 1 | 2008 | 337 | 0.070 |
Why?
| | Body Temperature | 1 | 2007 | 210 | 0.070 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 535 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 676 | 0.070 |
Why?
| | Blood Flow Velocity | 1 | 2008 | 390 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 253 | 0.070 |
Why?
| | Delivery of Health Care | 2 | 2023 | 835 | 0.070 |
Why?
| | Survivors | 1 | 2009 | 410 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2108 | 0.070 |
Why?
| | Mice, Knockout | 2 | 2022 | 2585 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2009 | 350 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2017 | 234 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2009 | 1398 | 0.060 |
Why?
| | Education, Medical, Graduate | 1 | 2009 | 374 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 4411 | 0.060 |
Why?
| | Genotype | 2 | 2020 | 1780 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 1843 | 0.050 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2023 | 43 | 0.050 |
Why?
| | Troponin | 1 | 2023 | 44 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1177 | 0.050 |
Why?
| | Travel | 1 | 2023 | 121 | 0.050 |
Why?
| | Adolescent | 4 | 2019 | 17862 | 0.050 |
Why?
| | Histone Deacetylase 6 | 1 | 2022 | 19 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2212 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 90 | 0.050 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 160 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 146 | 0.050 |
Why?
| | Catecholamines | 1 | 2022 | 96 | 0.050 |
Why?
| | Signal Transduction | 3 | 2021 | 4525 | 0.050 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 49 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2002 | 39 | 0.050 |
Why?
| | Calcium Channels | 1 | 2022 | 146 | 0.050 |
Why?
| | Prevalence | 2 | 2018 | 2255 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2022 | 4718 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 310 | 0.050 |
Why?
| | Graft Survival | 1 | 2023 | 464 | 0.050 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 10 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2022 | 339 | 0.050 |
Why?
| | Anaerobic Threshold | 1 | 2021 | 22 | 0.050 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2002 | 137 | 0.050 |
Why?
| | Phenylephrine | 1 | 2021 | 74 | 0.050 |
Why?
| | Chronic Disease | 2 | 2017 | 1591 | 0.050 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2020 | 11 | 0.050 |
Why?
| | Cardiomegaly | 1 | 2022 | 159 | 0.050 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 53 | 0.050 |
Why?
| | Culture Media | 1 | 2021 | 155 | 0.050 |
Why?
| | HEK293 Cells | 1 | 2023 | 590 | 0.050 |
Why?
| | Seizures | 1 | 2023 | 341 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 227 | 0.050 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2021 | 109 | 0.050 |
Why?
| | Prealbumin | 1 | 2020 | 22 | 0.040 |
Why?
| | Cytomegalovirus | 1 | 2021 | 145 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 431 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2020 | 59 | 0.040 |
Why?
| | Heart Valve Diseases | 1 | 2002 | 161 | 0.040 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2020 | 42 | 0.040 |
Why?
| | Electric Countershock | 1 | 2020 | 104 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 536 | 0.040 |
Why?
| | Norepinephrine | 1 | 2021 | 208 | 0.040 |
Why?
| | Acylation | 1 | 2019 | 28 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 386 | 0.040 |
Why?
| | Program Evaluation | 2 | 2017 | 825 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 61 | 0.040 |
Why?
| | Internship and Residency | 1 | 2009 | 941 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 172 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2020 | 91 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 176 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 208 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 250 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 458 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 316 | 0.040 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 8 | 0.040 |
Why?
| | Zebrafish | 1 | 2022 | 411 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 307 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2021 | 588 | 0.040 |
Why?
| | Fatty Acids | 1 | 2021 | 385 | 0.040 |
Why?
| | Fibroblasts | 1 | 2022 | 839 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4631 | 0.040 |
Why?
| | Lysine | 1 | 2019 | 242 | 0.040 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 80 | 0.040 |
Why?
| | Myosins | 1 | 2018 | 128 | 0.040 |
Why?
| | Collagen | 1 | 2020 | 416 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 165 | 0.040 |
Why?
| | Alleles | 1 | 2020 | 792 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2020 | 351 | 0.040 |
Why?
| | Tissue Donors | 1 | 2019 | 326 | 0.040 |
Why?
| | Fluorine Radioisotopes | 1 | 2017 | 10 | 0.040 |
Why?
| | Autoradiography | 1 | 2017 | 70 | 0.040 |
Why?
| | Circadian Rhythm | 1 | 2020 | 354 | 0.040 |
Why?
| | Diphenoxylate | 1 | 2016 | 5 | 0.040 |
Why?
| | Atropine | 1 | 2016 | 31 | 0.040 |
Why?
| | Loperamide | 1 | 2016 | 10 | 0.040 |
Why?
| | Antidiarrheals | 1 | 2016 | 15 | 0.040 |
Why?
| | Papio | 1 | 2017 | 96 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 372 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 141 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 633 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 746 | 0.030 |
Why?
| | Transcription Elongation, Genetic | 1 | 2016 | 20 | 0.030 |
Why?
| | Transcription Initiation Site | 1 | 2016 | 40 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 198 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2017 | 164 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 60 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 563 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3116 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 799 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 559 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 287 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 133 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 211 | 0.030 |
Why?
| | Actins | 1 | 2018 | 383 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 728 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 441 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 126 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1812 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2645 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1211 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2018 | 417 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 1955 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 24 | 0.030 |
Why?
| | Mass Screening | 1 | 2021 | 1012 | 0.030 |
Why?
| | Child, Preschool | 2 | 2019 | 9093 | 0.030 |
Why?
| | Reoperation | 1 | 2016 | 519 | 0.030 |
Why?
| | Action Potentials | 1 | 2017 | 406 | 0.030 |
Why?
| | Proteomics | 1 | 2019 | 844 | 0.030 |
Why?
| | Cobalt | 1 | 2014 | 46 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 999 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1636 | 0.030 |
Why?
| | Self Report | 1 | 2017 | 698 | 0.030 |
Why?
| | Warfarin | 1 | 2014 | 135 | 0.030 |
Why?
| | RNA Polymerase II | 1 | 2016 | 284 | 0.030 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 7 | 0.030 |
Why?
| | Heparin | 1 | 2014 | 222 | 0.030 |
Why?
| | Depression | 1 | 2021 | 1136 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1488 | 0.030 |
Why?
| | Creatine | 1 | 2013 | 50 | 0.030 |
Why?
| | Alanine | 1 | 2013 | 104 | 0.030 |
Why?
| | Chromatin | 1 | 2016 | 428 | 0.030 |
Why?
| | Glutamine | 1 | 2013 | 91 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 551 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 2563 | 0.030 |
Why?
| | Antibodies | 1 | 2014 | 372 | 0.030 |
Why?
| | Medication Adherence | 1 | 2017 | 537 | 0.030 |
Why?
| | Dyspnea | 1 | 2014 | 218 | 0.030 |
Why?
| | Fatigue | 1 | 2014 | 295 | 0.030 |
Why?
| | Phenotype | 1 | 2020 | 2815 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 850 | 0.020 |
Why?
| | Lactic Acid | 1 | 2013 | 278 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 767 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 1721 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2012 | 291 | 0.020 |
Why?
| | Child | 2 | 2019 | 18407 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 2894 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 900 | 0.020 |
Why?
| | Focus Groups | 1 | 2009 | 385 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 604 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6357 | 0.020 |
Why?
| | Infant | 1 | 2015 | 7945 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 899 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 298 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|